Lawyer, Trade-mark Agent
Tracey Stott practises intellectual property law with an emphasis on pharmaceutical patent litigation. She has particular experience in matters affecting the innovative pharmaceutical industry, including infringement and validity actions and proceedings under the Patented Medicines (Notice of Compliance) Regulations, and has appeared as counsel in matters before the Federal Court of Canada.
Dr. Stott’s graduate research involved the synthesis and study of metal-organic hybrid materials. Her research has been published in scientific journals.
Prior to joining our Toronto office, Dr. Stott practised with a leading national IP boutique.
Ph.D., Chemistry, University of British Columbia, 2005
B.Sc.(Hons.) Chemistry, Dalhousie University, 2000
LL.B., University of British Columbia, 2008
- Canada (trade-marks) 2012
- Ontario 2009
Memberships and activities
- Canadian Bar Association
- Ontario Bar Association
- Intellectual Property Institute of Canada
- Toronto Intellectual Property Group (executive, 5-year term)
- Canadian Society for Chemistry
- The Advocates’ Society
The Federal Court of Appeal dismissed BMS’s appeal from the Federal Court’s finding that claims for the bisulfate salt of atazanavir were obvious, and provided guidance on the meaning of “inventive concept” and the application of the leading Plavix decisions to obviousness..
April 25, 2017
The Federal Court dismissed Bristol-Myers Squibb’s prohibition application, finding that one of the patents had an overarching promise and lacked utility, and the other patent was “obvious to try.” .
March 29, 2017